Clinical trial Recruiting at 3 sites Interventional Ages 18 to 45 Women only

High-intensity, low-frequency rTMS to the right prefrontal cortex for heart-rate control in women with recurrent pregnancy loss and anxiety

Official title: High-intensity, Low-frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex for Acute Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Generalized Anxiety Disorder: a Randomized, Sham-controlled Mechanistic Trial (NEURO-CARD-rTMS-2)

Run by Shenyang Medical College · NCT07233278 · Data updated 2026-11-12

This test will see if a single session of high-intensity, low-frequency rTMS to the right dorsolateral prefrontal cortex can change heart rate and heart-rate variability in women with recurrent pregnancy loss who have anxiety.

Quick facts

Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment48 (estimated)
SponsorShenyang Medical College
Academic / other
Locations3 sites (Shenyang, Liaoning and 2 other locations)
StatusRecruiting
StartedNovember 19, 2025
Main results expectedJune 22, 2026
Study endsJanuary 12, 2027
Registry record updatedNovember 3, 2026
Trial IDNCT07233278 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–45, right-handed, not currently pregnant, with at least two prior pregnancy losses before viability and a DSM-5 anxiety disorder, who have no contraindications to TMS, would be ideal candidates.

Probably not a fit

People who are male, currently pregnant, have major organic cardiac or neurologic conditions, active substance use or other excluded psychiatric disorders, or contraindications to TMS are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, sham-controlled, proof-of-concept trial that delivers a single session of rhythmic low-frequency rTMS (120% resting motor threshold, 1 Hz) to the right dorsolateral prefrontal cortex with 20 consecutive 60-second stimulation windows. Participants are women aged 18–45 with a history of two or more pregnancy losses and a DSM-5 anxiety disorder, and they are compared to a matched sham stimulation group. The primary physiological outcomes are within-session heart rate changes and heart-rate-variability spectral power at the target rhythm (0.0167 Hz). The protocol builds on a prior dose-finding study and focuses on short-term modulation of cardiac autonomic markers rather than reproductive outcomes.

Why it matters

Potential benefit: If successful, the intervention could offer a noninvasive way to lower sympathetic drive and improve heart-rate variability in women with recurrent pregnancy loss and anxiety, potentially reducing stress-related cardiovascular risk.

How similar studies have gone: Early dose-finding work and small rTMS studies have shown that prefrontal stimulation can alter autonomic metrics, but this specific high-intensity, low-frequency rhythmic protocol for RPL with anxiety is a novel, proof-of-concept application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* (i) Female, aged 18-45 years, and right-handed;
* (ii) Diagnosed with recurrent pregnancy loss (RPL), defined as two or more consecutive spontaneous miscarriages occurring before 28 weeks of gestation;
* (iii) Not currently pregnant or in a state of missed miscarriage;
* (iv) Meeting the DSM-5 diagnostic criteria for GAD, with a HAMA score of at least 16, a CGI-S score of at least 4, and a HAMD-17 score of no more than 17.

Exclusion Criteria:

* (i) Contraindications to transcranial magnetic stimulation (TMS), such as metallic implants or a history of epilepsy;
* (ii) Unstable blood pressure (systolic \>180 mmHg or \<90 mmHg);
* (iii) Coexisting major organic disorders, including hyperthyroidism, atrial fibrillation, valvular heart disease, sinus bradycardia, neurological diseases, cerebrovascular disease, or pulmonary disorders;
* (iv) Significant suicide risk;
* (v) Other current major psychiatric disorders, including substance use disorder, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium. To preserve diagnostic homogeneity of the study sample, participants whose current primary diagnosis is another anxiety-related disorder will also be excluded, including panic disorder, social anxiety disorder, separation anxiety disorder, specific phobia, obsessive-compulsive and related disorders, and trauma- and stressor-related disorders; Current use of psychotropic medication at screening, or continuous use within the 4 weeks before screening of antidepressants, anxiolytics, antipsychotics, mood stabilizers, or sedative-hypnotics, in order to minimize hemodynamic confounding.

Where it's running

  • The Second Affiliated Hospital of Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting
  • Central Hospital Affiliated to Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting
  • 242 Hospital Affiliated to Shenyang Medical College
    Shenyang, Liaoning, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.